FDA rejects Merck insomnia drug, seeks lower-dose

FDA rejects Merck insomnia drug, seeks lower-dose

The FDA in its letter said 15 mg and 20 mg doses would be appropriate in patients in whom the 10 mg dose is well-tolerated but not effective, Merck said. ISI Group analyst Mark Schoenebaum said the manufacturing study could lead to about a one-year

6
Like
Save

Comments

Write a comment

*